GH / IGF-1 Axis Research
Both components are studied as tools for examining endogenous growth-hormone secretion and downstream IGF-1 signaling without exogenous GH.
Ishida et al. 2020≥99% Purity
TESA / IPA Blend
A growth-hormone stack that targets stubborn visceral fat
$135.00$67.50/vial with BOGO
USA madecGMP facility
QuantityBuy 1 Get 1 Free · auto-appliedAdd 2+ items to cart to activate the discount
Free Shipping on orders over $200
PASSEDSterility & Endotoxins
PASSEDNet Content & Purity
Researchers also added
Authenticity
Every vial is QR-authenticated
Scan the QR code on any vial to verify its batch, COA, and origin in seconds. Secure traceability from our lab to your bench.
About this compound
A body-composition stack pairing Tesamorelin with Ipamorelin — researched together for boosting growth hormone while targeting stubborn visceral (deep belly) fat.
Two-peptide research blend: GHRH(1-44) analog (Tesamorelin) + GHS pentapeptide (Ipamorelin)
- Formula
- Tesamorelin: C221H366N72O67S; Ipamorelin: C38H49N9O5
- Molecular weight
- 5135.8 g/mol
- Form
- Lyophilized powder
- CAS / ID
- Tesamorelin CAS 218949-48-5; Ipamorelin CAS 170851-70-4
0+
Published Studies
GH-axis secretagogue research
0
Active Compounds
Tesamorelin 12mg + Ipamorelin 2mg
0
Receptor Pathways
GHRH-R + GHS-R (ghrelin)
0
Research Areas
GH / IGF-1 Axis Research · GHRH-R + GHS-R Signaling · Body Composition Models & more
How It Works
How TESA / IPA Blend works
The pathways TESA / IPA Blend acts on — and what each one does. The animation traces its signal outward from the compound to every target it engages.
Signalling pathways studied in preclinical models · illustrative
GHRH Receptor Agonism
Tesamorelin Component
Tesamorelin is a synthetic, stabilized analog of human GHRH(1-44). It binds and activates pituitary GHRH receptors, stimulating endogenous growth-hormone secretion while preserving the body's normal pulsatile GH release pattern — unlike exogenous GH administration.
- Selective GHRH-receptor agonism at the pituitary
- Preserves physiological pulsatile GH secretion
- Stimulates downstream IGF-1 production
Selective GHS-R Agonism
Ipamorelin Component
Ipamorelin is a pentapeptide growth-hormone secretagogue that acts on the ghrelin receptor (GHS-R1a). It is noted as the first highly selective GHS — research shows it stimulates GH release without significantly raising ACTH, cortisol, or prolactin.
- Acts on the ghrelin receptor (GHS-R1a), a GHRP-like pathway
- Highly selective for GH release among secretagogues
- Minimal effect on cortisol, prolactin, ACTH in research models
Combined GH-Axis Stimulation
Dual-Pathway Design
Pairing a GHRH analog with a ghrelin-receptor secretagogue engages two distinct pituitary pathways. Research into GHRH + GHRP combinations examines whether the two mechanisms act in a complementary fashion on growth-hormone release.
- Targets GHRH-R and GHS-R simultaneously
- Studied as a complementary, two-pathway research model
- Both components act on endogenous GH secretion, not exogenous GH
Uses & Applications
What TESA / IPA Blend is researched for
The main areas TESA / IPA Blend is being studied for — and the study-reported figures behind them.
GHRH-R + GHS-R Signaling
Ipamorelin was characterized as the first selective GHS; pharmacological profiling confirmed it acts via a GHRP-like (ghrelin) receptor.
Raun et al. 1998Body Composition Models
Tesamorelin's Phase III research demonstrated GH-mediated reductions in visceral adipose tissue, making it a reference GHRH-analog research model.
Falutz et al. 2010Bone Mineral Content
In adult female rats, the GH secretagogues ipamorelin and GHRP-6 were shown to increase bone mineral content as measured by DXA.
Svensson et al. 2000Molecular Structure
The TESA / IPA Blend molecule
An interactive 3D model rendered from the compound record — rotate and explore its structure.
Tesamorelin: C221H366N72O67S; Ipamorelin: C38H49N9O5
Third-Party Verified
Independently tested. Verifiably pure.
Every batch of TESA / IPA Blend is sent to an accredited independent laboratory before it ships. Here is what we screen for.
- HPLC Purity AnalysisConfirms the peptide is ≥99% pure
- Mass SpectrometryVerifies the exact molecular identity
- Heavy Metals ScreeningLead, arsenic, cadmium & mercury — Pass
- Endotoxins (LAL)Bacterial endotoxin levels — Pass
- Sterility TestingNo microbial contamination — Pass
- Net Peptide ContentActual peptide mass per vial verified
Certificate of Analysis · Freedom DiagnosticPASS
- HPLC Purity
- ≥99%
- Identity
- Mass-spec confirmed
- Endotoxin (LAL)
- Pass
- Net content
- Verified
Compound Information
Full specification
| Product Type | Two-peptide research blend |
| Component 1 | Tesamorelin 12 mg — GHRH(1-44) analog |
| Component 2 | Ipamorelin 2 mg — GHS pentapeptide |
| Tesamorelin Molecular Weight | 5135.8 Da |
| Ipamorelin Molecular Weight | 711.86 g/mol |
| Total Peptide Content | 14 mg per vial |
| Form | Lyophilized powder |
| Purity | ≥99% (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage (Lyophilized) | -20°C for long-term stability |
| Storage (Reconstituted) | 2–8°C, use within 14 days |
| COA | Included with every order |
FAQ
Common questions about TESA / IPA Blend
TESA / IPA is a two-peptide research blend combining Tesamorelin (12 mg) — a stabilized analog of growth-hormone-releasing hormone — with Ipamorelin (2 mg), a selective growth-hormone secretagogue that acts on the ghrelin receptor. The two compounds engage different pituitary pathways involved in growth-hormone release.
Tesamorelin activates the GHRH receptor, mimicking the body's own growth-hormone-releasing hormone. Ipamorelin activates the ghrelin receptor (GHS-R1a), a separate GHRP-like pathway. Both ultimately stimulate endogenous GH secretion, but through distinct receptors — which is the rationale for studying them together.
GHRH analogs and growth-hormone-releasing peptides act on two different receptors in the pituitary. Research into combinations examines whether engaging both pathways produces a complementary effect on growth-hormone release compared with either mechanism alone.
Yes — Ipamorelin was described in the foundational 1998 research as the first selective growth-hormone secretagogue. Studies show it stimulates GH release without significantly increasing ACTH, cortisol, prolactin, or other pituitary hormones, even at doses well above the effective dose for GH release.
Tesamorelin is FDA-approved as a pharmaceutical (Egrifta) for a specific clinical indication. Ipamorelin is not approved for human use, and this specific TESA / IPA blend is not an approved product. It is supplied strictly for in vitro laboratory research and is not for human or veterinary use.
Lyophilized blend should be stored at -20°C, protected from light and moisture. Once reconstituted with bacteriostatic water, it should be kept at 2–8°C and used within approximately 14 days to preserve the integrity of both peptides.
Published Literature
Cited Sources
Peer-reviewed literature
Independent published research indexed from PubMed and peer-reviewed journals — not Eon Peptides claims.
[1]
PUBMED
[2]Ipamorelin, the First Selective Growth Hormone Secretagogue
View source PUBMED
[3]The GH Secretagogues Ipamorelin and GH-Releasing Peptide-6 Increase Bone Mineral Content in Adult Female Rats
View source PUBMED
[4]Effects of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients with Abdominal Fat Accumulation
View source JOURNAL
Growth Hormone Secretagogues: History, Mechanism of Action, and Clinical Development
View source For Research Use Only.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.